Equities

OXB

OXB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)422.50
  • Today's Change2.50 / 0.60%
  • Shares traded122.64k
  • 1 Year change+137.36%
  • Beta1.5987
Data delayed at least 20 minutes, as of Nov 25 2024 14:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments104141109
Total Receivables, Net205842
Total Inventory13139.52
Prepaid expenses4.363.983.21
Other current assets, total--0.020.07
Total current assets141216164
Property, plant & equipment, net7613470
Goodwill, net00.66--
Intangibles, net311050.05
Long term investments------
Note receivable - long term4.345.013.61
Other long term assets------
Total assets252460237
LIABILITIES
Accounts payable6.05145.26
Accrued expenses122314
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.653.300.85
Other current liabilities, total232013
Total current liabilities446033
Total long term debt1081118.49
Total debt1111149.34
Deferred income tax05.59--
Minority interest3.8332--
Other liabilities, total22488.10
Total liabilities17825650
SHAREHOLDERS EQUITY
Common stock484843
Additional paid-in capital380380308
Retained earnings (accumulated deficit)(355)(223)(164)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity74205187
Total liabilities & shareholders' equity252460237
Total common shares outstanding979686
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.